These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 33213057)

  • 1. The Molecular and Functional Characteristics of HLA-G and the Interaction with Its Receptors: Where to Intervene for Cancer Immunotherapy?
    Attia JVD; Dessens CE; van de Water R; Houvast RD; Kuppen PJK; Krijgsman D
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33213057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Significance of Immune Checkpoints HLA-G/ILT-2/4 and PD-L1 in Colorectal Cancer.
    Chen QY; Chen YX; Han QY; Zhang JG; Zhou WJ; Zhang X; Ye YH; Yan WH; Lin A
    Front Immunol; 2021; 12():679090. PubMed ID: 34054869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Killer Ig-like receptor 2DL4 does not mediate NK cell IFN-γ responses to soluble HLA-G preparations.
    Le Page ME; Goodridge JP; John E; Christiansen FT; Witt CS
    J Immunol; 2014 Jan; 192(2):732-40. PubMed ID: 24337374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibiting HLA-G restores IFN-γ and TNF-α producing T cell in pleural Tuberculosis.
    Saurabh A; Chakraborty S; Kumar P; Mohan A; Bhatnagar AK; Rishi N; Mitra DK
    Tuberculosis (Edinb); 2018 Mar; 109():69-79. PubMed ID: 29559123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of HLA-G/KIR2DL4 in Breast Cancer Immune Microenvironment.
    Zheng G; Jia L; Yang AG
    Front Immunol; 2022; 13():791975. PubMed ID: 35185887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-G/LILRBs: A Cancer Immunotherapy Challenge.
    Carosella ED; Gregori S; Tronik-Le Roux D
    Trends Cancer; 2021 May; 7(5):389-392. PubMed ID: 33563576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphisms and expression of HLA-G and its receptors, KIR2DL4 and LILRB1, in non-small cell lung cancer.
    Wiśniewski A; Kowal A; Wyrodek E; Nowak I; Majorczyk E; Wagner M; Pawlak-Adamska E; Jankowska R; Ślesak B; Frydecka I; Kuśnierczyk P
    Tissue Antigens; 2015 Jun; 85(6):466-75. PubMed ID: 25855135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA-G modulates immune responses by diverse receptor interactions.
    Hofmeister V; Weiss EH
    Semin Cancer Biol; 2003 Oct; 13(5):317-23. PubMed ID: 14708711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of human gamma delta [corrected] T-cell antitumoral activity through HLA-G: implications for immunotherapy of cancer.
    Lesport E; Baudhuin J; Sousa S; LeMaoult J; Zamborlini A; Rouas-Freiss N; Carosella ED; Favier B
    Cell Mol Life Sci; 2011 Oct; 68(20):3385-99. PubMed ID: 21337044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of iNKT Cells by the HLA-G-ILT2 Checkpoint and Poor Stimulation by HLA-G-Expressing Tolerogenic DC.
    Wu CL; Caumartin J; Amodio G; Anna F; Loustau M; Gregori S; Langlade-Demoyen P; LeMaoult J
    Front Immunol; 2020; 11():608614. PubMed ID: 33505397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-G/ILTs Targeted Solid Cancer Immunotherapy: Opportunities and Challenges.
    Lin A; Yan WH
    Front Immunol; 2021; 12():698677. PubMed ID: 34276691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble human leukocyte antigen-g5 activates extracellular signal-regulated protein kinase signaling and stimulates trophoblast invasion.
    Guo Y; Lee CL; So KH; Gao J; Yeung WS; Yao Y; Lee KF
    PLoS One; 2013; 8(10):e76023. PubMed ID: 24098421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to comment on "killer Ig-like receptor 2DL4 does not mediate NK cell IFN-γ responses to soluble HLA-G preparations".
    Le Page ME; Goodridge JP; John E; Christiansen FT; Witt CS
    J Immunol; 2014 May; 192(9):4003-4. PubMed ID: 24748632
    [No Abstract]   [Full Text] [Related]  

  • 14. Binding of HLA-G to ITIM-bearing Ig-like transcript 2 receptor suppresses B cell responses.
    Naji A; Menier C; Morandi F; Agaugué S; Maki G; Ferretti E; Bruel S; Pistoia V; Carosella ED; Rouas-Freiss N
    J Immunol; 2014 Feb; 192(4):1536-46. PubMed ID: 24453251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comment on "Killer Ig-like receptor 2DL4 does not mediate NK Cell IFN-γ responses to soluble HLA-G preparations".
    Rajagopalan S; Long EO
    J Immunol; 2014 May; 192(9):4003. PubMed ID: 24748631
    [No Abstract]   [Full Text] [Related]  

  • 16. The Killer Cell Ig-like Receptor 2DL4 Expression in Human Mast Cells and Its Potential Role in Breast Cancer Invasion.
    Ueshima C; Kataoka TR; Hirata M; Furuhata A; Suzuki E; Toi M; Tsuruyama T; Okayama Y; Haga H
    Cancer Immunol Res; 2015 Aug; 3(8):871-80. PubMed ID: 25735953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble HLA-G and HLA-G Bearing Extracellular Vesicles Affect ILT-2 Positive and ILT-2 Negative CD8 T Cells Complementary.
    Schwich E; Hò GT; LeMaoult J; Bade-Döding C; Carosella ED; Horn PA; Rebmann V
    Front Immunol; 2020; 11():2046. PubMed ID: 32973812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA-G: A New Immune Checkpoint in Cancer?
    Krijgsman D; Roelands J; Hendrickx W; Bedognetti D; Kuppen PJK
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA-G1, but Not HLA-G3, Suppresses Human Monocyte/Macrophage-mediated Swine Endothelial Cell Lysis.
    Eguchi H; Maeda A; Lo PC; Matsuura R; Esquivel EL; Asada M; Sakai R; Nakahata K; Yamamichi T; Umeda S; Deguchi K; Ueno T; Okuyama H; Miyagawa S
    Transplant Proc; 2016 May; 48(4):1285-7. PubMed ID: 27320605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells.
    LeMaoult J; Zafaranloo K; Le Danff C; Carosella ED
    FASEB J; 2005 Apr; 19(6):662-4. PubMed ID: 15670976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.